Title: Etnews– LG became a training academy for bio-ventures.

Publication: Etnews/Kyung Mi Moon

Date: 06 February 2013

Summary

• CEO Yong Zu Kim said “antibiotics, anticoagulants and oncology are what we have been researching since LegoChem was founded by experts from LG.”

• The company signed 7 license-out and 1 resource supply contracts and last year, it made a billion-dollar license-out contract with a global pharmaceutical company, AstraZeneca and another one with a domestic company.

• LegoChem passed the technology evaluation for KOSDAQ IPO.

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).